VEA
MLNT

Virtus ETF Advisers’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Virtus ETF Advisers’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-11,172
Closed -$221K – 414
2018
Q3 		$221K Sell
11,172
-8,201
-42% -$207K 0.02% 192
2018
Q2 		$615K Buy
19,373
+9,567
+98% +$344K 0.54% 130
2018
Q1 		$363K Buy
9,806
+5,395
+122% +$355K 0.32% 114
2017
Q4 		$348K Buy
+4,411
New +$326K 0.44% 95

Other funds holding MLNT

OH
Oikos Holdings New York $422M AUM 13.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Virtus ETF Advisers's MLNT Position: Q4 2018 in Review

Virtus ETF Advisers sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q4 2018, closing a stake of 11,172 shares — an estimated $221K sold.

Virtus ETF Advisers first reported a position in MLNT in Q4 2017 and held it in 4 quarters. The position peaked at $615K in Q2 2018. 77 funds tracked by Wall St. Rank hold MLNT as of Q4 2018.

  • Virtus ETF Advisers reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Virtus ETF Advisers sold 11,172 Melinta Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $221K.
  • Virtus ETF Advisers first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 4 quarters.
  • Virtus ETF Advisers's Melinta Therapeutics, Inc. Common Stock position peaked at $615K in Q2 2018.
  • 77 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Virtus ETF Advisers's 13F filing for Q4 2018, filed 5 Feb 2019.